Sudarshan Pharma to acquire 76% stake in Vizag-based pharma target

Listed-company acquisitionStrategic Transactions View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.2%Reaction day

₹36.00

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%-0.2% vs market

Specialty Chemicals peers, median of 94sector-0.1%-0.0% vs sector

On the reaction day the stock moved 0.2 pts less than Nifty Microcap 250 and in line with its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.2+0.1-0.2-0.1-0.0

Next day

-1.1+0.2-1.3-1.1+0.0

+3.8+0.6+3.3-0.9+4.7

+2.8-0.0+2.8-1.2+4.0

+6.3+0.5+5.7-1.3+7.5

+6.1+0.8+5.3-1.0+7.1

+6.4+0.6+5.8-1.0+7.5

15d

+9.7+1.3+8.4+0.6+9.0

+8.3-1.4+9.7-2.0+10.3

+1.7-0.6+2.2-0.9+2.5

—————

UpDownMarket · Nifty Microcap 250Sector · Specialty Chemicals peers, median of 94Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Sudarshan Pharma Industries has signed an MOU to acquire 76% (1.24 crore shares at Rs.10 each) in an unnamed Vizag-based pharma company with a 576.10 KL manufacturing plant across 4 blocks. Target holds US FDA, WHO Geneva, Anvisa, and ISO accreditations. Target turnover was Rs.15,437 lakhs in FY25-26, Rs.15,355 lakhs in FY24-25, and Rs.19,247 lakhs in FY23-24. Deal aims for backward integration and end-to-end manufacturing. Consideration is cash plus 40 lakh promoter shares. Target will become a subsidiary. Expected to close by 10 October 2026. Not a related party transaction.

Likely market impact

Strategic acquisition to make target a subsidiary, adding manufacturing capacity and global accreditations. Likely positive for long-term growth, pending due diligence.